Abnormal anandamide metabolism in celiac disease

Natalia Battista[a],[*],[1], Antonio Di Sabatino[b],[1], Monia Di Tommaso[a], Paolo Biancheri[b], Cinzia Rapino[a],
Francesca Vidali[b], Cinzia Papadia[c], Chiara Montana[c], Alessandra Pasini[b], Alberto Lanzini[d],
Vincenzo Villanacci[e], Gino R. Corazza[b],[1], Mauro Maccarrone[a],[f],[1]

[a]Department of Biomedical Sciences, University of Teramo, Teramo, Italy
[b]First Department of Medicine, Fondazione IRCCS Policlinico S. Matteo, Centro per lo Studio e la Cura della Malattia Celiaca, University of Pavia, Pavia, Italy
[c]Gastroenterology Unit, Parma University Hospital, Parma, Italy
[d]Department of Gastroenterology, University and Spedali Civili of Brescia, Brescia, Italy
[e]Pathology Unit, University and Spedali Civili of Brescia, Brescia, Italy
[f]European Center for Brain Research (CERC)/Santa Lucia Foundation, Rome, Italy

Abstract

The endocannabinoid system has been extensively investigated in experimental colitis and inflammatory bowel disease, but not in celiac disease, where only a single study showed increased levels of the major endocannabinoid anandamide in the atrophic mucosa. On this basis, we aimed to investigate anandamide metabolism in celiac disease by analyzing transcript levels (through quantitative real-time reverse transcriptase–polymerase chain reaction), protein concentration (through immunoblotting) and activity (through radioassays) of enzymes responsible for anandamide synthesis (*N*-acylphosphatidyl-ethanolamine specific phospholipase D, NAPE-PLD) and degradation (fatty acid amide hydrolase, FAAH) in the duodenal mucosa of untreated celiac patients, celiac patients on a gluten-free diet for at least 12 months and control subjects. Also, treated celiac biopsies cultured *ex vivo* with peptic–tryptic digest of gliadin were investigated. Our *in vivo* experiments showed that mucosal NAPE-PLD expression and activity are higher in untreated celiac patients than treated celiac patients and controls, with no significant difference between the latter two groups. In keeping with the *in vivo* data, the *ex vivo* activity of NAPE-PLD was significantly enhanced by incubation of peptic–tryptic digest of gliadin with treated celiac biopsies. On the contrary, *in vivo* mucosal FAAH expression and activity did not change in the three groups of patients, and accordingly, mucosal FAAH activity was not influenced by treatment with peptic–tryptic digest of gliadin. In conclusion, our findings provide a possible pathophysiological explanation for the increased anandamide concentration previously shown in active celiac mucosa.
© 2012 Elsevier Inc. All rights reserved.

Keywords: Duodenal mucosa; Endocannabinoid; FAAH; Gliadin; NAPE-PLD

1. Introduction

The endocannabinoid system comprises specific G-protein-coupled receptors, a variety of endogenous ligands including amides and esters of long-chain polyunsaturated fatty acids — among which anandamide (also known as *N*-arachidonoylethanolamine, AEA) and 2-arachidonoylglycerol are the main endogenous cannabinoid receptor agonists — and a machinery dedicated to endocannabinoid synthesis and degradation [1,2]. Besides their effects on the central nervous system and gastrointestinal motility [3], endocannabinoids are supposed to modulate the immune response [4], and their involvement in autoimmune and chronic inflammatory conditions has been recently proposed [5,6]. The demonstration of an abnormal expression/metabolism of endocannabinoids in various models of colitis and in patients with inflammatory bowel diseases has suggested that a dysregulation of the endogenous cannabinoid system might contribute to chronic intestinal inflammation [7,8]. Nevertheless, there is still little evidence on the contribution of endocannabinoids in celiac disease, a chronic inflammation of the small bowel induced in genetically susceptible individuals by an environmental irritant, gluten, with the possible participation of other environmental cofactors [9]. In particular, there is only one study showing higher AEA levels in the duodenal mucosa of active celiac patients in comparison to treated celiac patients and controls [10]. In the present study, we aimed to explore AEA metabolism by investigating mRNA, protein and activity of enzymes responsible for the synthesis (*N*-acylphosphatidyl-ethanolamine specific phospholipase D, NAPE-PLD) [11] and degradation (fatty acid amide hydrolase, FAAH) [12] of AEA in the duodenal mucosa of untreated celiac patients, celiac patients on a gluten-free diet and control subjects. Moreover, through

* Corresponding author. Department of Biomedical Sciences, University of Teramo, Piazza A. Moro 45, 64100 Teramo, Italy. Tel.: +39 0861 266844; fax: +39 0861 266843.
E-mail address: nbattista@unite.it (N. Battista).

[1] Natalia Battista and Antonio Di Sabatino contributed equally to this manuscript and should be considered joint first authors; Gino R. Corazza and Mauro Maccarrone should be considered joint last authors.

ex vivo experiments, we investigated the effect of the peptic–tryptic digest of gliadin (PT-gliadin) on AEA metabolism in organ culture biopsies taken from treated celiac patients.

2. Materials and methods

2.1. Materials

AEA was purchased from Sigma Chemical Co. (St. Louis, MO, USA). [^{3}H]AEA (60 Ci/mmol) and *N*-[^{3}H]arachidonoylphosphatidyl-ethanolamine ([^{3}H]NArPE, 200 Ci/mmol) were from ARC (St. Louis, MO, USA). Rabbit anti-NAPE-PLD polyclonal antibody was from Novus Biologicals Inc. (Littleton, CO, USA). Rabbit anti-FAAH, anti-β-actin polyclonal antibodies and secondary antibodies conjugated to horseradish peroxidase were from Santa Cruz Biotechnologies (Santa Cruz, CA, USA).

2.2. Patients and tissues

Biopsies were collected from the second part of the duodenum of 10 patients affected by uncomplicated untreated celiac disease (four males and six females, mean age 34.6 years, range 19–45). The diagnosis was based on positivity of serum antiendomysial antibodies associated with the typical histopathological lesions, namely, villous atrophy, increased intraepithelial lymphocyte infiltration and crypt hyperplasia. Four patients showed a Marsh IIIc lesion, and six showed a Marsh IIIb lesion. Duodenal biopsies were also collected from 10 patients affected by uncomplicated celiac disease on a gluten-free diet for at least 12 months (two males and eight females, mean age 35.6 years, range 22–66), all negative for serum antiendomysial antibodies, and with a substantially normal duodenal mucosal architecture. Finally, duodenal biopsies were also collected from 11 subjects (three males and eight females, mean age 48.5 years, range 21–70) undergoing upper endoscopy for functional dyspepsia, negative for antiendomysial antibodies and with normal histology. Informed consent was obtained in all cases, and the study was approved by the Ethical Committee of University of Brescia. Some of the biopsies were processed for routine histology, some were used for organ culture experiments, and others were directly snap frozen and stored at −70°C.

2.3. Organ culture

Biopsy specimens, placed on grids in the central well of an organ culture dish, were cultured in an airtight container with 95% O$_2$/5% CO$_2$ at 37°C in the absence or presence of 1 mg/ml PT-gliadin (Frazer III fraction; Sigma-Aldrich, Poole, UK) added to the medium containing RPMI-1640 medium (Gibco, Invitrogen, Paisley, UK) supplemented with 10% HL-1 (Lonza BioWhittaker, Verviers, Belgium), 100 U/ml penicillin and 100 mg/ml streptomycin [13]. After 24-h culture, biopsies were snap frozen and stored at −70°C.

2.4. Quantitative real-time reverse transcriptase–polymerase chain reaction (qRT-PCR) analysis

RNA was extracted from CD specimens using the RNeasy extraction kit (Qiagen, Crawley, UK), as suggested by the manufacturer. Quantitative RT-PCR assays were performed using the SuperScript III Platinum Two-Step qRT-PCR Kit (Invitrogen, Carlsbad, CA, USA). The target transcripts were amplified by means of an ABI PRISM 7700 sequence detector system (Applied Biosystems, Foster City, CA, USA), using the primer reported in Table 1. β-Actin was used as housekeeping gene for quantity normalization. One microliter of the first strand of cDNA product was used for amplification (in triplicate) in 25-μl reaction solution containing 12.5 μl of Platinum SYBR Green qPCR SuperMix-UDG (Invitrogen, Carlsbad, CA, USA) and 10 pmol of each primer. The following PCR program was used: 95°C for 10 min and 40 amplification cycles at 95°C for 30 s, 56°C for 30 s and 72°C for 30 s.

2.5. AEA metabolism

The synthesis of [^{3}H]AEA through the activity of NAPE-PLD (E.C. 3.1.4.4) was assayed in tissue homogenates (100 μg/test), using 100 μM [^{3}H]NArPE [14], by means of reversed-phase high-performance liquid chromatography, as reported [15]. The hydrolysis of [^{3}H]AEA by FAAH was assayed in tissue homogenates (50 μg/test) by measuring the release of [^{3}H]ethanolamine, as reported [16].

2.6. Western blotting

Western blotting was performed according to standard procedures [17]. In brief, tissue samples were lysed in ice-cold lysis buffer (10 mM EDTA, 50 mM pH 7.4 Tris-HCl, 150 mM sodium chloride, 1% Triton-X-100, 2 mM phenylmethylsulfonyl fluoride, 2 mM sodium orthovanadate, 10 mg/ml leupeptin and 2 mg/ml aprotinin), and the amount of protein was determined by the Bio-Rad Protein assay (Bio-Rad Laboratories, Hemel Hempstead, UK). An equal amount of protein (20 μg) was loaded onto 10% sodium dodecyl sulfate–polyacrylamide gels and blotted onto polyvinylidene fluoride sheets (Amersham Biosciences, Piscataway, NJ, USA) under reducing conditions. Membranes were blocked with 10% nonfat dried milk and 5% bovine serum albumin for 2 h and then incubated with rabbit

Table 1
Oligonucleotide sequences in qRT-PCR for NAPE-PLD, FAAH and β-actin detection

mRNA target	Forward	Reverse
NAPE-PLD	5′-TTGTGAATCCGTGGCCAACATGG-3′	5′-TACTGCGATGGTGAAGCACG-3′
FAAH	5′-CCCAATGGCTTAAAGGACTG-3′	5′-ATGAACCGCAGACACAAC-3′
β-Actin	5′-TGACCCAGATCATGTTTGAG-3′	5′-TTAATGTCACGCAGATTTCC-3′

anti-NAPE-PLD (diluted 1:100), rabbit anti-FAAH (diluted 1:300) or mouse anti-β-actin (1:1000 dilution) antibodies. Membranes were rinsed and incubated with the appropriate horseradish-peroxidase-conjugated secondary antibody (diluted 1:2000) in blocking solution. Detection was performed using West Dura Chemiluminescence System (Pierce, Rockford, IL, USA). Protein expression levels were quantified by densitometric analysis using the ImageJ software after normalization with β-actin.

2.7. Enzyme-linked immunosorbent assay (ELISA)

Interferon (IFN)-γ in organ culture supernatants was measured using the IFN-γ ELISA kits (R&D Systems, Abingdon, UK) according to the manufacturer's instructions.

2.8. Statistical analysis

Results are expressed as mean±S.E.M., and each experiment was performed in triplicate. Data were analyzed by means of Prism 5 program (GraphPad Software, San Diego, CA, USA) using the one-way analysis of variance followed by Bonferroni's *post hoc* analysis. A level of *P*<.05 was considered statistically significant.

3. Results

3.1. Mucosal NAPE-PLD and FAAH mRNA

The presence of AEA metabolizing enzymes was tested at the transcriptional level by qRT-PCR analysis in biopsies collected from the duodenum of untreated celiac patients, treated celiac patients and control subjects (Fig. 1A–B). As shown in Fig. 1A, NAPE-PLD mRNA levels in the active celiac mucosa were significantly higher (up to threefold) in comparison to control mucosa (*P*<.05) and treated celiac mucosa (*P*<.01). However, no difference in NAPE-PLD mRNA levels was observed between control mucosa and treated celiac mucosa. Conversely, the expression of FAAH mRNA did not significantly differ in the three groups of patients (Fig. 1B).

3.2. Mucosal NAPE-PLD and FAAH protein expression and activity

The translation of NAPE-PLD and FAAH mRNAs into the corresponding proteins was assessed by Western blotting analysis (Fig. 2A–B). The densitometric analysis showed that NAPE-PLD protein expression had a


Fig. 1. Quantitative RT-PCR analysis of NAPE-PLD (A) and FAAH (B) in the duodenal mucosa of untreated celiac patients (UCD), treated celiac patients (TCD) and control subjects (CS). *P*<.05 UCD vs. CS. #*P*<.01 UCD vs. TCD.

Fig. 2. Western blotting of NAPE-PLD and FAAH (upper panel) in the duodenal mucosa of UCD, TCD and CS. Mouse brain and mouse spleen were used as positive controls for NAPE-PLD and FAAH, respectively (data not shown). Expression levels of NAPE-PLD (A) and FAAH (B) were evaluated by densitometric analysis after normalization with β-actin. A.U., arbitrary units.

similar trend compared to the expression at the mRNA level detected by qRT-PCR. Although the difference did not reach statistical significance, the expression of NAPE-PLD protein was slightly increased in untreated celiac patients compared to control subjects, whereas it was comparable in control mucosa and treated celiac mucosa (Fig. 2A). Likewise, FAAH protein expression mirrored *faah* gene expression (Fig. 2B). Untreated celiac patients showed higher NAPE-PLD activity with respect to healthy subjects (143 ± 10 vs. 78 ± 10 pmol/min per mg of protein, $P<.05$) (Fig. 3A), while AEA synthase activity was appreciably lower in treated than in untreated celiac patients (42 ± 3 vs. 143 ± 10 pmol/min per mg of protein, $P<.01$) (Fig. 3A). No statistical difference was observed in FAAH


Fig. 3. Activity of NAPE-PLD (A) and FAAH (B) measured in the duodenal mucosa of UCD, TCD and CS. *$P<.05$ UCD vs. CS. #$P<.01$ UCD vs. TCD.


Fig. 4. *Ex vivo* mucosal activity of NAPE-PLD (A) and FAAH (B) measured in treated celiac biopsies cultured for 24 h with PT-gliadin. To verify whether gliadin challenge was effective in eliciting a Th1 immune response, IFN-γ levels were measured by ELISA in the organ culture supernatants (C). *$P<.05$ and **$P<.001$ vs. vehicle.

activity among control subjects (170 ± 26 pmol/min per mg of protein), untreated celiac patients (158 ± 13 pmol/min per mg of protein) and treated celiac patients (199 ± 18 pmol/min per mg of protein) (Fig. 3B).

3.3. Ex vivo effect of PT-gliadin on mucosal NAPE-PLD and FAAH activity

To verify the effect of gluten on AEA metabolism, we measured NAPE-PLD and FAAH activity in the mucosal biopsy specimens from treated celiac patients after 24-h incubation with 1 mg/ml PT-gliadin (Fig. 4A–C). We found that NAPE-PLD activity was significantly ($P<.05$) up-regulated by PT-gliadin incubation (30 ± 3 vs. 47 ± 5 pmol/min per mg protein) (Fig. 4A), while no effect was exerted by PT-gliadin on FAAH activity (120 ± 18 vs. 125 ± 26 pmol/min per mg protein) (Fig. 4B). To verify whether our *ex vivo* system was functional, we measured IFN-γ levels in the supernatants of treated celiac biopsies, and as expected [13], we found that IFN-γ was significantly ($P<.001$) up-regulated by incubation with PT-gliadin incubation (249 ± 54 vs. 120 ± 32 pg/ml) (Fig. 4C).

4. Discussion

In the present study, we showed that the *in vivo* expression/activity of the main AEA-synthesizing enzyme NAPE-PLD, but not of the main AEA-degrading enzyme FAAH, is increased in active celiac mucosa. These findings provide a possible pathophysiological explanation for the increased AEA concentration shown by D'Argenio et al. [10] in the duodenal mucosa of untreated celiac patients. Further, we demonstrated that the *ex vivo* incubation of treated celiac biopsies with PT-gliadin significantly increased the activity of NAPE-PLD. There is evidence from experimental studies that the endocannabinoid system is involved in intestinal inflammation [3,7,18,19]. In particular, FAAH-deficient mice are protected from 2,4-dinitrobenzene sulfonic acid-induced colitis, while a pharmacological blockade of cannabinoid receptor 1 leads to a worsening of murine colitis [20]. On this basis, we recently examined the levels of endocannabinoids in the inflamed mucosa of inflammatory bowel disease patients, and we found that the content of AEA is reduced as a consequence of both defective synthesis and increased degradation [8]. Moreover, we provided evidence that the synthetic AEA analogue methanandamide exerts anti-inflammatory *in vitro* and *ex vivo* functions on lamina propria mononuclear cells isolated from inflammatory bowel disease patients

[8], thus supporting the view that targeting the endocannabinoid system could offer a possible alternative therapeutic strategy in patients with Crohn's disease and ulcerative colitis [7]. It should be underlined that the endocannabinoid system has been extensively explored in the large intestine [3,7], while no investigation has been conducted in the small bowel tract with the exception of the study by D'Argenio et al. [10], who showed higher AEA concentrations in the duodenum of untreated celiac patients. On this basis, we wondered whether this increase was secondary to a dysregulated AEA metabolism. Our *in vivo* data showed that mRNA, protein and activity levels of the main enzyme responsible for AEA synthesis, NAPE-PLD, increased in untreated celiac mucosa compared to treated celiac mucosa and control mucosa, without any significant difference between treated celiac patients and control subjects. Although the biosynthesis of AEA is a complex mechanism and it has been recently hypothesized that additional pathways may account for the conversion of *N*-arachidonoyl phosphatidylethanolamine into AEA [21], NAPE-PLD is still considered the main pathway responsible for AEA production. Unlike NAPE-PLD, the expression/activity of FAAH remained unchanged in the three groups of patients examined. According to the *in vivo* data, *ex vivo* experiments showed that mucosal activity of NAPE-PLD, but not FAAH, was up-regulated by the incubation of treated celiac biopsies with PT-gliadin. Further studies are needed to clarify the molecular events underlying gluten-induced up-regulation of NAPE-PLD. It is difficult to explain why the abnormal biosynthetic pathway of AEA is the opposite in inflammatory bowel disease (down-regulation of NAPE-PLD activity) [8] compared to celiac disease (up-regulation of NAPE-PLD activity), as both disorders are characterized by Th1-induced chronic inflammation [22]. However, the different sites of inflammation (colon and duodenum, respectively) might account for this discrepancy. In conclusion, our findings showing increased expression and activity of the AEA-synthesizing enzyme NAPE-PLD in the mucosa of untreated celiac patients support the view that the AEA metabolism is abnormal in celiac disease, and provide a possible pathophysiological explanation for the increased AEA concentration previously shown in active celiac mucosa [8]. The unchanged AEA levels in treated celiac mucosa together with the observation that gliadin up-regulates the *ex vivo* activity of NAPE-PLD suggest that this alteration might be secondary to gluten-induced damage. Further studies are needed to elucidate the mechanisms underlying gluten-induced up-regulation of NAPE-PLD in celiac disease.

Acknowledgments

References

[1] Muccioli GG. Endocannabinoid biosynthesis and inactivation, from simple to complex. Drug Discov Today 2010;15:474–83.
[2] Petrosino S, Ligresti A, Di Marzo V. Endocannabinoid chemical biology: a tool for the development of novel therapies. Curr Opin Chem Biol 2009;13:309–20.
[3] Izzo AA, Camilleri M. Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Gut 2008;57:1140–55.
[4] Tanasescu R, Constantinescu CS. Cannabinoids and the immune system: an overview. Immunobiology 2010;215:588–97.
[5] Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 2005;5:400–11.
[6] Croxford JL, Yamamura T. Cannabinoids and the immune system: potential for the treatment of inflammatory diseases? J Neuroimmunol 2005;166:3–18.
[7] Izzo AA, Sharkey KA. Cannabinoids and the gut: new developments and emerging concepts. Pharmacol Ther 2010;126:21–38.
[8] Di Sabatino A, Battista N, Biancheri P, Rapino C, Rovedatti L, Astarita G, et al. A key role for the endogenous cannabinoid system in the gut mucosa of inflammatory bowel disease patients. Mucosal Immunol 2011;4:574–83.
[9] Di Sabatino A, Corazza GR. Celiac disease. Lancet 2009;373:1480–93.
[10] D'Argenio G, Petrosino S, Gianfrani C, Valenti M, Scaglione G, Grandone I, et al. Overactivity of the intestinal endocannabinoid system in celiac disease and in methotrexate-treated rats. J Mol Med 2007;85:523–30.
[11] Ueda N, Tsuboi K, Uyama T. Enzymological studies on the biosynthesis of *N*-acylethanolamines. Biochim Biophys Acta 2010;1801:1274–85.
[12] Fezza F, De Simone C, Amadio D, Maccarrone M. Fatty acid amide hydrolase: a gate-keeper of the endocannabinoid system. Subcell Biochem 2008;49:101–32.
[13] Di Sabatino A, Pickard KM, Gordon JN, Salvati V, Mazzarella G, Beattie RM, et al. Evidence for the role of interferon-alfa production by dendritic cells in the Th1 response in celiac disease. Gastroenterology 2007;133:1175–87.
[14] Okamoto Y, Morishita J, Tsuboi K, Tonai T, Ueda N. Molecular characterization of a phospholipase D generating anandamide and its congeners. J Biol Chem 2004;279:5298–305.
[15] Fezza F, Gasperi V, Mazzei C, Maccarrone M. Radiochromatographic assay of *N*-acyl-phosphatidylethanolamine-specific phospholipase D activity. Anal Biochem 2005;339:113–20.
[16] Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, Tarzia G, et al. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 2005;313:352–8.
[17] Di Sabatino A, Jackson CL, Pickard KM, Buckley M, Rovedatti L, Leakey NAB, et al. Transforming growth factor-β signalling and matrix metalloproteinases in the mucosa overlying Crohn's disease strictures. Gut 2009;58:777–89.
[18] Kunos G, Pacher P. Cannabinoids cool the intestine. Nat Med 2004;10:678–9.
[19] Smid SD. Gastrointestinal endocannabinoid system: multifaceted roles in the healthy and inflamed intestine. Clin Exp Pharmacol Physiol 2008;35:1383–7.
[20] Massa F, Marsicano G, Hermann H, Cannich A, Monory K, Cravatt BF, et al. The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 2004;113:1202–9.
[21] Simon GM, Cravatt BF. Characterization of mice lacking candidate *N*-acyl ethanolamine biosynthetic enzymes provides evidence for multiple pathways that contribute to endocannabinoid production in vivo. Mol Biosyst 2010;6:1411–8.
[22] MacDonald TT, Monteleone G. Immunity, inflammation, and allergy in the gut. Science 2005;307:1920–5.